Reports Q2 revenue $21.85M, consensus $23.96M. “Our immediate priority is completing the submission of a New Drug Application in the very near term for UGN-102, which we believe has the potential to be a practice-changing therapy for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer,” said Liz Barrett, President and Chief Executive Officer of UroGen. “The compelling body of clinical data, including the ENVISION trial, which demonstrated an unprecedented 82.3% 12-month duration of response by Kaplan-Meier analysis in patients who had previously achieved a complete response at three months, reinforces the opportunity for UGN-102 to be the first FDA-approved medicine for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- Is URGN a Buy, Before Earnings?
- UroGen Pharma Shareholders Shape Governance and Incentives
- UroGen Pharma 5M share Spot Secondary priced at $17.50
- UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
- UroGen Pharma announces offering of ordinary shares, warrants